The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

While deal teams celebrate fast approvals, it can create a crisis for integration leads. Cisco's Splunk deal closed six months sooner than expected, forcing an acceleration of complex integration planning. This compression puts pressure on synergy timelines, as execution must begin immediately at close without the anticipated planning runway.

To achieve a 4% growth rate by 2031, large pharma firms need to acquire $69 billion in new sales. However, an analysis shows only 28 suitable public targets existed recently, and 10 have already been acquired in the last two years, creating a stark supply-demand imbalance for late-stage assets.

The biopharma M&A landscape is no longer dominated solely by Big Pharma. A new class of well-capitalized biotechs like Argenx and Vertex has emerged as active buyers. This increases competition for assets and provides more exit options for smaller companies, altering deal dynamics for everyone.

An M&A "super cycle" is unlikely because the most attractive targets—companies with successful assets—are increasingly choosing to "go it alone." Inspired by companies like Vertex and Regeneron, they are shrinking the pool of willing sellers.

The biotech ecosystem is a continuous conveyor belt from seed funding to IPO, culminating in acquisition by large biopharma. The recent industry-wide stall wasn't a failure of science, but a halt in M&A activity that backed up the entire system.

Deals like Neurocrin buying Soleno and Servier buying Day One illustrate a trend of mid-sized drug makers becoming significant buyers. This expands the pool of potential bidders beyond just large-cap pharma, creating more competitive M&A processes that can benefit selling companies and their investors.

M&A is often framed as a win, but it can be detrimental to patients. The acquisition of an aggressive, fast-moving biotech by a large pharma company can lead to slowed development timelines and more conservative regulatory strategies, ultimately delaying access to life-saving treatments.

While celebrated, the current wave of high-value acquisitions of promising companies like Sonora and Halda has a downside. It removes potential standalone success stories from the market, potentially weakening the public biotech index and depriving investors of future mid-cap growth engines.